SYRS - Rasio utang marang kapitalisasi buku Syros

High R&D costs and stringent FDA oversight create significant barriers for Syros Pharmaceuticals (SYRS). This total debt-to-equity chart provided by GURU.Markets confirms a reliance on external financing, as the value remains at 0.00. The lack of current sales is offset by grants, while future exclusivity for its cancer therapy will provide the company with monopoly pricing power.

Assessing the financial stability of Syros Pharmaceuticals (SYRS) requires an analysis of its capital structure. This indicator measures the proportion of borrowed funds to equity, determining the level of debt load. By examining the financial leverage chart based on book capitalization, an investor can track solvency dynamics without reporting delays. A decrease in this ratio confirms the success of the liability restructuring. Focus now shifts to clinical trial catalysts for leukemias.